- Home
- FTHY vs CRVS Comparison
FTHY vs CRVS Comparison
Compare FTHY & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FTHY | CRVS |
|---|---|---|
| Founded | 2020 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 539.8M | 546.7M |
| IPO Year | N/A | 2016 |
Fundamental Metrics
Financial Performance| Metric | FTHY | CRVS |
|---|---|---|
| Price | $14.23 | $25.23 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $28.00 |
| AVG Volume (30 Days) | 176.7K | ★ 7.1M |
| Earning Date | 01-01-0001 | 11-04-2025 |
| Dividend Yield | ★ 10.93% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.66 | $2.54 |
| 52 Week High | $14.74 | $26.95 |
Technical Indicators
Market Signals| Indicator | FTHY | CRVS |
|---|---|---|
| Relative Strength Index (RSI) | 61.40 | 91.48 |
| Support Level | $14.03 | $6.46 |
| Resistance Level | $14.28 | $7.18 |
| Average True Range (ATR) | 0.10 | 1.66 |
| MACD | 0.01 | 2.20 |
| Stochastic Oscillator | 83.87 | 91.63 |
Price Performance
Historical ComparisonAbout FTHY First Trust High Yield Opportunities 2027 Term Fund
FIRST TRUST HIGH YIELD OPPORTUNITIES 2027 TERM FUND is a diversified, closed-end management investment company. The investment objective of the fund is to provide current income. The fund invests a majority of its managed assets in high-yield debt securities of any maturity that are rated below investment grade at the time of purchase or unrated securities. Its investment portfolio comprises corporate bonds and notes, senior floating-rate loan interests, foreign corporate bonds and notes, money market funds, and other instruments across various industries.
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).